Core Viewpoint - The company, Ruida New Materials, announced the approval of a proposal to use temporarily idle raised funds for cash management, with a limit of up to RMB 1.3 billion [1] Group 1 - The second meeting of the company's second board was held on August 21, 2025, where the cash management proposal was reviewed and approved [1] - The company will ensure that the use of these funds does not affect the construction of investment projects and will effectively control risks [1] - The funds can be used for a rolling period of 12 months from the date of approval by the shareholders' meeting, with any single investment amount not exceeding the approved limit [1]

Summary of Key Points Core Viewpoint - The company, Shanghai Aopumai Biotechnology Co., Ltd., plans to utilize part of its idle raised funds for cash management, with a maximum investment amount of RMB 700 million, ensuring high safety and liquidity in the investment products chosen [1][2][8]. Investment Overview - **Investment Purpose**: The aim is to maximize shareholder value by improving the efficiency of fund usage while ensuring that the use of raised funds is not affected and risks are effectively controlled [2][6]. - **Investment Amount and Duration**: The company intends to use up to RMB 700 million for cash management, with the funds being able to roll over within a 12-month period [2][5]. - **Source of Funds**: The funds are sourced from the proceeds of the company's initial public offering, which raised a total of approximately RMB 1.64 billion after deducting issuance costs [2][5]. Investment Methodology - The company will invest in high-safety, liquid financial products such as agreement deposits, structured deposits, time deposits, notice deposits, large certificates of deposit, and income certificates [1][5][6]. - The cash management products will not be used for pledging or for investment purposes in securities [5][6]. Approval Process - The board of directors and the supervisory board approved the cash management proposal during meetings held on August 21, 2025, with a validity period of 12 months from the date of approval [2][6][8]. - The management team has been authorized to make investment decisions and sign relevant contracts, with the finance department responsible for implementation [1][6]. Opinions from Supervisory Board and Sponsor - The supervisory board supports the cash management initiative, stating it will not affect the use of raised funds or harm the interests of the company and its shareholders [7][8]. - The sponsor, Guotai Junan Securities, has confirmed that the cash management plan complies with relevant regulations and will enhance fund usage efficiency without altering the intended use of raised funds [8].

中信证券股份有限公司 关于广东丸美生物技术股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"）作为广东丸美生物技术股 份有限公司（以下简称"丸美生物"或"公司"）首次公开发行股票的保荐人， 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司章程指引》 《证券发行上市保荐业务管理办法》 《上市公司募集资金监管规则》 《上海证券交 易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等有关规定，对丸美生物使用部分闲置募集资金进行现金管理事项进行了审 慎核查，核查情况及核查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准广东丸美生物技术股份有限公司首次 公开发行股票的批复》 （证监许可[2019]917 号）核准，并经上海证券交易所同意， 丸美生物首次公开发行人民币普通股（A 股）股票 4,100 万股，发行价格为每股 人民币 20.54 元。共计募集资金人民币 84,214.00 万元，扣除各项发行费用人民 币 5,213.80 万元后的募集资金净额为人民币 79,000.20 万元。上述募集资金到位 情 ...

Group 1 - The core viewpoint of the article is that Yifang Biotechnology (Shanghai) Co., Ltd. plans to utilize part of its idle raised funds for cash management to enhance fund efficiency and returns for the company and its shareholders [1][2][5] Group 2 - The total amount of raised funds is RMB 208,380 million, with an issuance price of RMB 18.12 per share, approved by the China Securities Regulatory Commission on April 1, 2022 [1] - The company intends to use up to RMB 1 billion of temporarily idle raised funds for cash management, with a validity period of 12 months from the approval date by the board of directors [2] - The investment products will include low-risk, high-liquidity financial products such as structured deposits, time deposits, and large certificates of deposit, with a maximum investment period of 12 months [2] Group 3 - The decision to use idle funds for cash management was approved in the fifth meeting of the second board of directors on August 21, 2025, ensuring that it will not affect the normal operation of the company's main business or the progress of investment projects [2][4] - The company has established a robust approval and execution process for purchasing cash management products to ensure fund safety, including the use of dedicated settlement accounts [3][4] Group 4 - The sponsor, CITIC Securities, has verified that the company has followed necessary decision-making procedures and complies with relevant laws and regulations regarding the use of idle raised funds for cash management [5][6]

证券代码：603983 证券简称：丸美生物 公告编号：2025-022 广东丸美生物技术股份有限公司 关于使用部分闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 广东丸美生物技术股份有限公司（以下简称"公司"或"丸美生物"）于 2025 年 8 月 21 日召开了第五届董事会第七次会议，审议通过了《关于使用部分闲置 募集资金进行现金管理的议案》，拟使用不超过人民币 20,000 万元的闲置募集 资金进行现金管理，该额度可滚动使用，自公司第五届董事会第七次会议审议通 过之日起十二个月内有效，并提请授权管理层行使决策权并签署相关合同文件， 具体事项由公司财务部负责组织实施。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准广东丸美生物技术股份有限公司首次 公开发行股票的批复》（证监许可[2019]917 号）核准，并经上海证券交易所同 意，丸美生物首次公开发行人民币普通股（A 股）股票 4,100 万股，发行价格为 每股人民币 20.54 元。共计募集资金人民币 84,214.00 万 ...

Meeting Overview - The fifth meeting of the board of directors of Guangdong Marubi Biotechnology Co., Ltd. was held on August 21, 2025, with all 9 directors present [1] - The meeting was convened in compliance with relevant laws and regulations, and the resolutions passed are legally valid [1] Resolutions Passed - All resolutions were approved with 9 votes in favor, 0 against, and 0 abstentions [2][3] - The resolutions included the approval of the 2025 semi-annual report and the special report on the use of raised funds [2] Financial Decisions - The company and its subsidiaries are authorized to apply for a comprehensive credit limit of up to 1.2 billion RMB for various financing activities [3] - A cash dividend of 2.50 RMB (including tax) per 10 shares will be distributed to shareholders based on the total share capital on the record date [3] Upcoming Events - The company will hold its first extraordinary general meeting of 2025 to review the proposed resolutions [4]

南京国博电子股份有限公司（以下简称"公司"）第二届监事会第六次会议 于 2025 年 8 月 22 日以通讯方式召开，会议通知及资料于 2025 年 8 月 15 日以电 子邮件形式送达公司全体监事。本次会议由公司监事会主席孙博女士召集和主 持，会议应出席监事 3 人，实际到会监事 3 人。本次会议的召集、召开及表决符 合有关法律、法规和《南京国博电子股份有限公司章程》的规定，作出的决议合 法、有效。 二、监事会会议审议情况 证券代码：688375 证券简称：国博电子 公告编号：2025-028 南京国博电子股份有限公司 第二届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 经与会监事审议表决，形成会议决议如下： （一）审议通过《关于公司使用部分闲置募集资金进行现金管理的议案》 经审查，监事会认为：公司本次使用部分闲置募集资金不超过 44,100.00 万元（含本数）进行现金管理，内容及审议程序符合《上市公司募集资金监管规 则》《上海证券交易所科创板上市公司自律监管指引第 ...

2025年8月22日，*ST松发（603268）七届董事会一次会议通过议案，同意在不影响募投项目、确保资 金安全前提下，用不超5亿元暂时闲置募集资金进行现金管理，购买保本型储蓄产品，期限12个月，资 金可循环使用；同时以协定存款方式存放本次定增配套资金。公司此次募资净额39.32亿元，已对募投 项目投资额调整。 ...

Group 1 - The board meeting was held on August 20, 2025, with all 7 directors present, and the meeting complied with relevant laws and regulations [1][2] - The board approved the use of raised funds to replace self-raised funds used for project investments and issuance expenses, totaling 264,100 RMB (excluding VAT) [1][2] - The board agreed to use up to 330 million RMB of idle raised funds for cash management, focusing on low-risk, high-liquidity financial products with a maximum investment period of 12 months [2][3] Group 2 - The board approved the temporary use of up to 100 million RMB of idle raised funds to supplement working capital, limited to operations related to the main business, with a maximum usage period of 12 months [3][4] - The board agreed to use self-owned funds and bank acceptance bills to pay for project expenses, with plans to replace these with raised funds later [4][5] - The board unanimously agreed to hold the second temporary shareholders' meeting on September 8, 2025 [5]

Group 1 - The core point of the news is the approval of several proposals by the Supervisory Board of Ningbo Yokogawa Precision Industrial Co., Ltd. regarding the use of raised funds and cash management [1][2][3][4][5] Group 2 - The Supervisory Board meeting was held on August 20, 2025, with all three supervisors present, and the meeting complied with relevant laws and regulations [1] - The proposal to replace self-raised funds with raised funds for pre-invested projects and paid issuance expenses was approved, amounting to 264,100 yuan (excluding VAT) [1][2] - The proposal to use up to 330 million yuan of idle raised funds for cash management in safe and liquid products was approved, with a maximum investment period of 12 months [2][3] - The proposal to temporarily supplement working capital with up to 100 million yuan of idle raised funds was approved, limited to a maximum period of 12 months [3][4] - The proposal to use self-owned funds and bank acceptance bills for project payments, later to be replaced with raised funds, was approved, ensuring compliance with regulations and no impact on project progress [4][5]